Last updated on April 17, 2014 at 15:43 EDT

Competitor Analysis: Biosimilar and Biosuperior Therapeutic Antibodies

July 1, 2013

DUBLIN, July 1, 2013 /PRNewswire/ –

Research and Markets (
http://www.researchandmarkets.com/research/zsvknx/competitor) has announced the
addition of the “Competitor Analysis: Biosimilar and Biosuperior Therapeutic Antibodies”
[http://www.researchandmarkets.com/research/zsvknx/competitor ] report to their offering.

http://photos.prnewswire.com/prnh/20130307/600769 )

This report provides a competitor evaluation in the field of recombinant monoclonal
and polyclonal antibodies in the market, in the pipeline as next generation products and
as biosimilar versions as of December 2012. Purchase of the downloadable PDF report
includes a 6-month online access to the data of the report and any updates since the
publication date. Credentials to access the database will be sent by e-mail and allow
online work with the project data to print or export an individual report.

Marketed antibodies are attractive for companies to create next generation variants
and biosimilar copies because they represent clinically and commercially validated
products. New technologies such as Fc engineering, polyclonal mixtures, antibody drug
conjugates or bi-specific molecules as well as the expiration of patents stimulate the
discovery and development of biosimilar and bio-superior/bio-better molecules.

The cumulated sales volume of therapeutic antibodies
[http://www.researchandmarkets.com/research/zsvknx/competitor ] for which biosimilar
antibodies are in the R&D pipeline was as high as US$ 54.7 billion in the year 2011 with
double digit growth rates of many representative of them:

        - Rituxan/MabThera
        - Arzerra
        - Erbitux
        - Vectibix
        - Herceptin
        - Avastin
        - Lucentis
        - Enbrel
        - Remicade
        - Humira
        - Cimzia
        - Simponi
        - Actemra/RoActemra
        - ReoPro
        - Campath
        - Orencia
        - Tysabri
        - Xolair
        - Synagis
        - Prolia/Xgeva
        - Soliris
        - Stelara
        - Zenapax

More than 140 biosimilar antibodies are in the pipeline with the first molecules
approved in non-regulated markets. The regulation of the development of biosimilar
antibodies in the European Union has facilitated the submission of an MAA of a first
biosimilar antibody from a Korean company.

The report includes a compilation of currently active projects in research and
development of biosimilar and bio-superior antibodies against commercially and clinically
validated targets:

        - CD20
        - Her2
        - VEGF
        - TNF
        - EGF-R
        - CD52
        - GPIIb/IIIa
        - B7.1/B7.2 (CD80/CD86)
        - IL-6R
        - Alpha4/beta1/7 integrin
        - IgE
        - RSV
        - RANKL
        - Complement C5
        - IL-12/IL-23
        - CD25 (IL-2R)

Competitor projects are listed in a tabular format providing information on:

        - Drug Codes,
        - Target / Mechanism of Action,
        - Class of Compound,
        - Company,
        - Product Category,
        - Indication,
        - R&D Stage and
        - additional comments with a hyperlink leading to the source of information.

For more information visit


        Research and Markets
        Laura Wood, Senior Manager.
        U.S. Fax: 646-607-1907
        Fax (outside U.S.): +353-1-481-1716
        Sector: Pharmaceuticals
         [http://www.researchandmarkets.com/categories.asp?cat_id=16&campaign_id=zsvknx ]



SOURCE Research and Markets

Source: PR Newswire